InflaRx to Present at Upcoming Investor Conferences

Rhea-AI Summary

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company, announced management will present at two virtual investor conferences in March 2021. The H.C. Wainwright Global Life Sciences Conference will feature an on-demand presentation by CEO Prof. Niels C. Riedemann on March 9, 2021, starting at 7:00 am EST. Meanwhile, the Oppenheimer 31st Annual Healthcare Conference will host a live presentation on March 16, 2021, at 8:00 am EST. InflaRx focuses on developing innovative anti-inflammatory therapies targeting the complement system.

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will present at two upcoming virtual investor conferences.

H.C. Wainwright Global Life Sciences Conference
March 9-10, 2021
An on-demand corporate presentation from Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, will be available starting at 7:00 am EST (1:00 pm CET) on March 9, 2021. A webcast of the event will be accessible on the InflaRx website in the Investors section under Events & Presentations.

Oppenheimer 31^st Annual Healthcare Conference
Tuesday, March 16, 2021 at 8:00 am EST (1:00 pm CET)
A live webcasted corporate presentation from Prof. Riedemann will be available on the InflaRx website in the Investors section under Events & Presentations. A replay of the presentation will be accessible on InflaRx’s website following the live event.

About InflaRx N.V.:
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information please visit www.inflarx.com.

Contacts:

InflaRx N.V.
Jordan Zwick – Chief Strategy Officer
Email: IR@inflarx.de
Tel: +1 917-338-6523

MC Services AG
Katja Arnold, Laurie Doyle, Andreas Jungfer
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
US: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials; the impact of the COVID-19 pandemic on the Company; the timing and our ability to commence and conduct clinical trials; potential results from current or potential future collaborations; our ability to make regulatory filings, obtain positive guidance from regulators, and obtain and maintain regulatory approvals for our product candidates; our intellectual property position; our ability to develop commercial functions; expectations regarding clinical trial data; our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies; the industry in which we operate; the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in InflaRx’s periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

FAQ

What is the date and time of InflaRx's presentation at the H.C. Wainwright Global Life Sciences Conference?

InflaRx will present on March 9, 2021, starting at 7:00 am EST.

How can I access the webcast of InflaRx's presentations?

The webcasts will be available on the InflaRx website in the Investors section under Events & Presentations.

When will InflaRx present at the Oppenheimer 31st Annual Healthcare Conference?

InflaRx's presentation at the Oppenheimer conference is scheduled for March 16, 2021, at 8:00 am EST.

What technology does InflaRx focus on developing?

InflaRx focuses on developing therapies targeting the complement system, specifically anti-C5a technology.

Who will be presenting for InflaRx at the upcoming conferences?

Prof. Niels C. Riedemann, CEO and Founder of InflaRx, will be presenting at both conferences.